Korea United Pharm Inc.

KRX:033270.KS

21500 (KRW) • At close September 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 278,943.297262,522.023221,039.963215,949.553221,310.875211,935.53197,023.264176,905.09162,045.985155,189.553136,891.13134,829.851145,453.053134,958.313119,084.23594,700.34659,695.98467,591.173
Cost of Revenue 105,455.242117,234.41398,380.22390,757.55892,723.0686,458.79185,161.74380,075.24774,526.74872,097.34264,725.77659,453.08856,066.64948,895.43239,809.88927,916.77717,709.53621,150.521
Gross Profit 173,488.055145,287.609122,659.74125,191.994128,587.814125,476.738111,861.52196,829.84387,519.23783,092.2172,165.35475,376.76389,386.40486,062.88179,274.34666,783.56941,986.44846,440.652
Gross Profit Ratio 0.6220.5530.5550.580.5810.5920.5680.5470.540.5350.5270.5590.6150.6380.6660.7050.7030.687
Reseach & Development Expenses 33,197.23115,535.63213,791.5112,269.21814,099.24912,442.0874,899.8424,005.0383,803.3073,988.6193,004.7941,299.0431,271.6251,529.791,195.7391,888.6931,844.6772,233.282
General & Administrative Expenses 16,011.73816,138.83917,131.18916,923.26519,945.41820,192.59519,949.58619,415.39218,044.81717,342.75116,301.66615,985.08318,927.03423,391.3626,572.25328,210.36813,280.07411,638.369
Selling & Marketing Expenses 20,743.20718,549.04116,684.48215,984.87918,943.33614,797.10614,385.27412,305.86511,165.81911,531.14111,230.42811,551.71812,828.16513,279.23412,636.26411,172.2788,615.3729,422.973
SG&A 83,228.12834,687.8833,815.67132,908.14438,888.75434,989.70134,334.8631,721.25729,210.63628,873.89227,532.09427,536.80131,755.19936,670.59439,208.51739,382.64621,895.44621,061.342
Other Expenses -1,788.93646,850.93541,827.24339,888.69440,600.9872,761.914138.082476.8571,008.871106.617991.1271,987.324716.273-1,614.314-2,375.939-684.731-118.035-402.5
Operating Expenses 118,214.29597,074.44789,434.42485,066.05693,588.9987,726.13680,144.44369,711.62664,604.55661,105.24157,328.17355,566.64966,526.36364,307.40860,056.18854,552.90934,965.41839,333.95
Operating Income 55,273.75948,213.16233,225.31640,125.93834,479.47437,750.60331,717.07827,118.21722,914.68121,986.96914,837.18119,810.11423,577.55121,755.47419,218.15912,230.6617,021.0327,106.703
Operating Income Ratio 0.1980.1840.150.1860.1560.1780.1610.1530.1410.1420.1080.1470.1620.1610.1610.1290.1180.105
Total Other Income Expenses Net 3,794.0225,211.6536,257.912-4,475.6574,054.5592,187.972-3,199.695338.4651,926.527792.583731.77751.715-852.214-2,441.367-3,948.488-1,446.715-692.253-2,181.999
Income Before Tax 59,067.78153,424.81539,483.22835,650.28238,534.03339,938.57528,517.38327,456.68224,841.20822,779.55215,568.95120,561.82922,725.33819,314.10715,269.67110,783.9466,328.7794,924.704
Income Before Tax Ratio 0.2120.2040.1790.1650.1740.1880.1450.1550.1530.1470.1140.1530.1560.1430.1280.1140.1060.073
Income Tax Expense 11,821.928,149.72110,834.4799,037.0257,618.0868,266.127653.7327,942.9183,119.7754,300.2213,364.7324,191.4112,527.9262,470.6521,070.1051,909.551753.252973.947
Net Income 48,261.71445,275.09428,648.74926,613.25730,915.94631,672.44727,863.65119,513.76521,721.43318,374.83612,212.39216,378.8320,208.05816,843.45514,199.5668,874.3965,575.5263,950.757
Net Income Ratio 0.1730.1720.130.1230.140.1490.1410.110.1340.1180.0890.1210.1390.1250.1190.0940.0930.058
EPS 3,297.933,057.781,930.091,793.762,086.922,139.21,8821,2771,3841,163759.81,059.81,398.041,127.45932.35591.18372.55266.67
EPS Diluted 3,277.483,038.181,917.771,787.062,086.162,1391,8821,2771,3841,160750.981,059.81,386.271,112.75922.55591.18371.57266.67
EBITDA 65,367.93569,734.61251,942.12448,744.63949,902.82952,207.03636,964.71637,126.87631,796.79930,936.38922,765.1726,595.6928,558.46424,667.96820,438.23715,673.6810,026.0649,599.682
EBITDA Ratio 0.2340.2660.2350.2260.2250.2460.1880.210.1960.1990.1660.1970.1960.1830.1720.1660.1680.142